Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessPublished version of a preprint
The DOI matches its Crossref record; 331 of the 348 references it cites were found in a registry or an index; 216 of the 381 sources its claims cite were checked for support.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
Overview
CoChat Summary
TL;DR
This 2022 ADA/EASD consensus report updates person-centered management of hyperglycemia in nonpregnant adults with type 2 diabetes, emphasizing holistic care, weight management, physical activity, DSMES, and individualized medication selection. It gives strongest priority to GLP-1 receptor agonists and SGLT2 inhibitors for people with established or high-risk cardiovascular, kidney, or heart failure disease, based on evidence synthesized from trials and meta-analyses published through 13 June 2022.
Key findings
- A PubMed search identified randomized controlled trials, systematic reviews, and meta-analyses published in English between 28 January 2018 and 13 June 2022; the report built on the 2012, 2015, 2018, and 2019 consensus statements.
- In a network meta-analysis of 453 trials across nine drug classes, the greatest HbA1c reductions were seen with insulin regimens and GLP-1 RA; subcutaneous semaglutide had the greatest body-weight reduction, and SGLT2i and GLP-1 RA had the greatest blood-pressure reductions.
- In comparative effectiveness analyses, SGLT2i were superior to GLP-1 RA for reducing heart failure hospitalization and a composite kidney outcome, while GLP-1 RA appeared more efficacious for stroke; no important differences were evident for mortality or other cardiovascular outcomes.
- The report states that DSMES significantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective; it also reports specific trial effects such as STEP 2 weight loss of 9.6% with semaglutide 2.4 mg, and AWARD-11 and SUSTAIN FORTE showing greater HbA1c and weight reductions with higher-dose GLP-1 RA.
Methods
- Consensus report written by an ADA/EASD panel, using prior consensus reports as the starting point and incorporating evidence from publications since 2018.
- Evidence source: PubMed search for English-language RCTs, systematic reviews, and meta-analyses published between 28 January 2018 and 13 June 2022, plus reference-list screening for additional studies.
- Evidence appraisal: papers were grouped by topic, subgroup meta-analyses were assessed for credibility using relevant guidance, and recommendations were informed by GRADE; draft recommendations were reviewed by invited reviewers and opened for public comment.
Limitations
- The paper states that subgroup analyses should not be regarded as conclusive and should be formally appraised and ideally complemented by relevant RCTs.
- The text notes that evidence is limited for some populations because of underrepresentation in trials, including younger people, older adults, women, and non-White participants; this is an evident limitation of generalizability.
- The report also makes evident that some conclusions rely on network meta-analyses, observational data, and nonrandomized studies, and that some outcomes (e.g., long-term cardiovascular profile of tirzepatide) were still pending, which limits certainty.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
140 Valid · 9 Not valid · 61 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
What the sources say
- Not checked — no full text of the sourcecites [223] Tsapas, 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis, Ann Intern Med source
- Disputedcites [259] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured
The Results > Outcomes section reports fewer non-fatal myocardial infarctions with both drug classes in low-risk patients and fewer non-fatal strokes with GLP-1 receptor agonists. That contradicts the claim that no drug class benefits cardiovascular events in this group. The Discussion > Clinical uncertainties section cautions that trials generally did not include the lowest-risk patients and does not judge whether the absolute effects are clinically notable. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As with any laboratory test, HbA1c measurement has limitations (2,52).”
What the sources say
- Supportedcites [2] Draznin, 2022, 6. Glycemic targets: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The “A1C Limitations” section (p. 2) explicitly says the A1C test is subject to limitations and that its measurement varies, as with any laboratory test. (LLM, conf=0.95)
- Supportedcites [52] American Diabetes Association Professional Practice Committee, 2022, 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The Fasting and 2-Hour Plasma Glucose section explicitly refers to “these limitations with A1C,” including lower diagnostic sensitivity and imperfect correlation with average glucose in some individuals. The Race/Ethnicity/Hemoglobinopathies section also notes that hemoglobin variants can interfere with A1C measurement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, these multifaceted domains (heterogeneity across individual characteristics, social determinants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when attempting to integrate diabetes care into daily life (49).”
What the sources say
- Supportedcites [49] Young-Hyman, 2016, Psychosocial care for people with diabetes: a position statement of the American Diabetes Association, Diabetes Care source
The Introduction says complex environmental, social, behavioral, and emotional factors challenge people with diabetes and their families as they integrate care into daily life. Life Course Considerations identifies social determinants and person-based characteristics as factors providers should consider, while the Conclusions describes challenges to providing that care. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40).”
What the sources say
- Supportedcites [39] Ahlqvist, 2018, Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, Lancet Diabetes Endocrinol source
The Abstract describes type 2 diabetes as highly heterogeneous and identifies age at diagnosis, BMI, and insulin resistance as clustering variables. It reports that the resulting clusters differed in patient characteristics and risk of complications, supporting the claimed variation. (LLM, conf=0.92)
- Supportedcites [40] Pigeyre, 2022, Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial, Diabetologia source
The Introduction describes heterogeneity in diabetes presentation and progression. The Results identify subgroups differing in age at diagnosis, BMI and insulin-resistance-related characteristics; the Abstract reports differences in renal outcomes between subgroups. Together, these passages support the cited statement about variation among people with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High-quality evidence has consistently shown that DSMES signi fi cantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective (22,25 -30).”
What the sources say
- Not checked — no full text of the sourcecites [22] Draznin, 2022, 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022, Diabetes Care source
- Partly supportedcites [25] Chrvala, 2016, Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control, Patient Educ Couns sourceExperimental — accuracy not yet measured
The Introduction says evidence from randomized and observational studies suggests DSME is cost-effective. The citing sentence presents cost-effectiveness as a consistently demonstrated finding, whereas this review does not establish it; Practical implications says DSME must be cost-effective, not that the review found it to be so. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [26] Pillay, 2015, Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis, Ann Intern Med source
- Not checked — no full text of the sourcecites [27] Zhao, 2017, Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, J Adv Nurs source
- Partly supportedcites [28] Odgers-Jewell, 2017, Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression, Diabet Med sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says group-based education for people with type 2 diabetes may be more cost-effective than individual education because it requires less time and funding. That qualified comparison does not establish the broader, unqualified claim that DSMES is cost-effective. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [29] He, 2017, Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis, Endocrine source
- Not checked — no full text of the sourcecites [30] Chatterjee, 2018, Diabetes structured self-management education programmes: a narrative review and current innovations, Lancet Diabetes Endocrinol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
127 more claims · 71 with their cited sources checked
Create a free account to see all 237 claims and every source verdict.
- It may state two separate claims as one. 88
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DiRECT dietary intervention was highly costeffective and deliverable in primary care. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“thus cost-savings might be greater. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be particularly important in young-onset T2D where higher rates of obesity, more rapid deterioration in blood glucose levels and earlier development of diabetes complications have been observed [9,95].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increase insulin secretion regardless of glycemia, typically resulting in 2–3 kg weight gain [44].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [44]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 20×
“Notably, the benefits of GLP-1 RA and SGLT2i for cardiovascular and renal outcomes have been found to be independent of metformin use, and thus these agents should be considered in people with established or high risk of CVD, HF, or CKD, independent of metformin use (173–175).”
BackgroundInfluential
Research works printed but not linked: 2
- Nathan, Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study, N Engl J Med
- Nathan, Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes, N Engl J Med
Cited by
Items 401–500 of 2,053
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
Guo, L., Zhang, B., Xue, X., Zhang, B., Cai, H., Jiang, H., Zhang, L., Jin, P., Wang, X., Cheng, Z., et al. (2025) · Nature · doi:10.1038/s41586-025-10031-z · Cited by 22
Mazdutide versus placebo in Chinese adults with type 2 diabetes
Zhu, D., Zhao, J., Cai, H., Chu, X., Xiu, S., Song, C., Cheng, Z., Cao, H., Jiang, H., Zhang, L., et al. (2025) · Nature · doi:10.1038/s41586-025-10026-w · Cited by 21
SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes
Jensen, S. K., Heide‐Jørgensen, U., Andersen, I. T., Bonnesen, K., Fu, E. L., Thomsen, R. W., & Christiansen, C. F. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.7409 · Cited by 13
Verma, S., Sabbour, H. M., Alamuddin, N., Alawadi, F., Alkandari, H., Almahmeed, W. A., Assaad-Khalil, S. H., HADDAD, J. A., Lombard, L., Malik, R. A., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15011 · Cited by 11
Aroda, V. R., Frías, J. P., Ji, L., Niemoeller, E., Nguyên‐Pascal, M., Denkel, K., Espinasse, M., Guo, H., Baek, S. J., Choi, J., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15079 · Cited by 14
“The American Diabetes Association (ADA) and the European Association for the Study of Diabetes guidelines recommend glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as the first injectable medication for people with type 2 diabetes (T2D) with suboptimal glycaemic control, either alone or in combination with oral…”
BackgroundSelf-citationFineman, M. S., Bryant, C. L. N., Colbert, K., Jozefiak, T. H., Petersen, J. S., Horowitz, M., Vora, J. P., Rayner, C. K., Wabnitz, P. A., & Nimgaonkar, A. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15066 · Cited by 11
“Nausea 1 (33) [1] 1 (33) [1] 4 (67) [5] 1 (33) [1] 7 (29) [8] 7 (22)”
Seksaria, S., Dutta, B. J., Kaur, M., Gupta, G. D., Bodakhe, S. H., & Singh, A. (2023) · Current Diabetes Reviews · doi:10.2174/1573399820666230809152148 · Cited by 12
Nicholls, S. J., Tofé, S., le Roux, C. W., D’Alessio, D. A., Wiese, R. J., Pavo, I., Brown, K., Weerakkody, G. J., Zeytinoglu, M., & Romera, I. C. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02147-9 · Cited by 11
“Modest weight loss of 5–10% has traditionally been a realistic goal for both preventing T2D and improving glycemic and metabolic control in people with T2D [41– 43].”
BackgroundAdelakun, S. A., Aniah, J. A., Omotoso, O. D., & Arowosegbe, O. A. (2024) · Aspects of Molecular Medicine · doi:10.1016/j.amolm.2024.100034 · Cited by 18
Zhang, H., Gao, B., Zheng, G., et al. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107428 · Cited by 11
Cases, A., Broseta, J. J., Marqués, M., Guldris, S. C., Mauro, J. C. J., Arroyo, R. A., & Ortíz, A. (2024) · Nefrología · doi:10.1016/j.nefro.2024.05.001 · Cited by 18
State Out-Of-Pocket Caps On Insulin Costs: No Significant Increase In Claims Or Utilization
Anderson, K. E., Chaiyakunapruk, N., Gutierrez, E. J., Schmutz, H. W., Rose, M. R., Brixner, D. I., & McQueen, R. B. (2024) · Health Affairs · doi:10.1377/hlthaff.2024.00118 · Cited by 15
Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023
Hamblin, P. S., Earnest, A., Russell, A. W., Talic, S., Zomer, E., & Zoungas, S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15893 · Cited by 13
“20 Pioglitazone remains available, but along with acarbose, annual utilization trends have been negative for the past decade for both, and they appear to have only niche roles.”
InfluentialBruno, S., Daddoveri, F., Galante, M. D., Bazzani, A., Sanabria, F. C., Colitta, A., D’Ascanio, P., Frumento, P., & Faraguna, U. (2024) · Sleep Health · doi:10.1016/j.sleh.2024.08.003 · Cited by 14
Davis, G. M., Peters, A. L., Bode, B. W., Carlson, A. L., Dumais, B., Vienneau, T. E., Huyett, L. M., & Ly, T. T. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15993 · Cited by 14
Bain, S. C., Belmar, N., Hoff, S. T., Husain, M., Rasmussen, S., Vilsbøll, T., & Petrie, M. C. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01659-7 · Cited by 17
“It is, therefore, important to avoid treatments associated with hypoglycemia and problematic, symptomatic hypotension in this older population [5].”
InfluentialPalmas, V., Deledda, A., Heidrich, V., Sanna, G., Cambarau, G., Fosci, M., Puglia, L., Cappai, E. A., Lai, A., Loviselli, A., et al. (2025) · Metabolites · doi:10.3390/metabo15010022 · Cited by 14
“Modern guidelines recommend a holistic, patient-centered approach, tailored to the individual needs of each patient [32].”
Hopkins, R., Young, K., Thomas, N. J., Jones, A. G., Hattersley, A. T., Shields, B. M., Dennis, J., & McGovern, A. P. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16163 · Cited by 16
Abdullah, Z., Cui, Y., Platt, R. W., Renoux, C., Azoulay, L., Xia, C., & Yu, O. H. Y. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004541 · Cited by 13
Pavon, J. M., Schlientz, D., Maciejewski, M. L., Economou-Zavlanos, N., & Lee, R. (2025) · Diabetes Care · doi:10.2337/dci24-0079 · Cited by 17
Persson, V., & Wickman, U. L. (2025) · Healthcare · doi:10.3390/healthcare13080950 · Cited by 18
“Education gives the patient knowledge about their disease and is an important part of preventing complications and increasing self-care to achieve a better quality of life [26].”
Tonin, G., Goričar, K., Blagus, T., Janež, A., Dolžan, V., & Klen, J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1547920 · Cited by 18
Boye, K. S. (2021) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2021.15.555904 · Cited by 13
Lim, L., Lau, E. S. H., Chan, S. P., Ji, L., Lim, S. K., Sirinvaravong, S., Unnikrishnan, A., Luk, A. O. Y., Cortese, V., Durocher, A., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110855 · Cited by 18
Stumpf, M. A. M., Cercato, C., de Melo, M. E., Santos, R. D., & Mancini, M. C. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad280 · Cited by 12
Long‐term safety and efficacy of SGLT2 inhibitor use in older east Asians with type 2 diabetes
Takahashi, Y., Seino, Y., & Yabe, D. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14097 · Cited by 11
“Based on these additional bene-fi ts, SGLT2 inhibitors are internationally and domestically recommended for patients with type 2 diabetes with heart failure, chronic kidney disease (CKD), and cardiovascular diseases 3,4 .”
BackgroundChang, H., Chen, Y., Kuo, T., Lin, Y., Chien, K., Chang, H., Hung, C., & Chung, F. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032397 · Cited by 15
BALDASSARRE, M. P. A., Dalmazi, G. D., Coluzzi, S., Carrieri, F., Febo, F., Centorame, G., Cassino, P., Piacentino, L., Baroni, M. G., Consoli, A., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113054 · Cited by 13
“…guidelines for the management of hyperglycemia in T2D in adults published on 2022 state that a medication with proven cardiovascular benefits should be prescribed to all patients with diabetes at high or very high cardiovascular risk (CVD) regardless of glycated hemoglobin (HbA1c) level [12].”
BackgroundChang, C. R., Roach, L. A., Russell, B. M., & Francois, M. E. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112072 · Cited by 11
“A primary goal in the treatment and management of T2D is to prevent or reduce progression/development of diabetes complications by reducing hyperglycemia and improving glycemic control [3].”
Management of Early-Onset Type 2 Diabetes in Adults: Current Evidence and Future Directions
Savage, M. J., Goldney, J., Slater, T., Sarkar, P., Sargeant, J. A., Wilmot, E. G., & Davies, M. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0561 · Cited by 11
“Indeed, intensive interventions incorporating very-low energy diets and increased physical activity have been increasingly recognised as effective methods of improving T2DM management in adults and children [74].”
InfluentialSelf-citationLim, E. C. N., & Lim, C. E. D. (2025) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-025-02079-9 · Cited by 17
“This reflects a more balanced view of potential aspiration risks against proven therapeutic benefits, especially for diabetes and cardiovascular care [11, 12].”
Kreutz, R. H., Canbay, A., Haluzík, M., Januszewicz, A., Mendive, J. M., Sarafidis, P. A., & Schattenberg, J. M. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106902 · Cited by 19
Morieri, M. L., Longato, E., Camillo, B. D., Sparacino, G., Avogaro, A., & Fadini, G. P. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01712-4 · Cited by 11
Salem, A. M. H., Harris, D. E., Bray, J. J. H., Obaid, D. R., Stephens, J. W., & Halcox, J. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.02.004 · Cited by 11
Cellular mechanism of diabetes remission by bariatric surgery
Ye, J., Hu, Y.-X., Wang, C., Lian, H., & Dong, Z. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.07.001 · Cited by 12
YEUNG, Y. L., Lee, K. Y., Lau, E. S. H., Yung, T.-F., Yang, A., Wu, H., Wong, K. T., Kong, A. P. S., Chow, E., Ronald, C. W., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1284799 · Cited by 10
Kristensen, F., Svane, H. M. L., Laugesen, K., Al-Mashhadi, S. K., Christensen, D. H., Sørensen, H. T., & Skajaa, N. (2025) · European Stroke Journal · doi:10.1177/23969873241260956 · Cited by 16
“28 Several limitations of our study must be emphasized.”
López, M. A. B., Camafort, M., Ruíz, R. C., Cuenca, A. M. C., Gargallo-Fernández, M., de Paz, H. D., Redondo‐Antón, J., Artime, E., Díaz‐Cerezo, S., & Santos, M. R. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02938-2 · Cited by 11
Fano, M. D., Falorni, A., Malara, M., Porcellati, F., & Fanelli, C. G. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s466328 · Cited by 14
Pantanetti, P., Ronconi, V., Sguanci, M. E., Palomares, S. M., Mancin, S., Tartaglia, F. C., Cangelosi, G., & Petrelli, F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164752 · Cited by 12
“Among them, glucagon-like peptide-1 receptor agonists (GL-1RAs) are considered to have a very high efficacy for not only glucose lowering but also for addressing other cardiometabolic risk factors [4,5].”
BackgroundHassanein, M. M., Malek, R., Sifri, S. A., Sahay, R. K., Büyükbeşe, M. A., Djaballah, K., Melas‐Melt, L., & Shaltout, I. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01642-2 · Cited by 12
Razaghizad, A., Ni, J., Marques, P. S., Mavrakanas, T. A., Tsoukas, M. A., Possik, E., Huynh, T. T., Edwards, J. D., Liu, P. P., Swardfager, W., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15768 · Cited by 12
“24 Nevertheless, our findings showed that this low-risk phenotype experienced the greatest numerical benefit from SGLT2 inhibition with respect to risk reduction for hospitalization for heart failure and fatal or non-fatal myocardial infarction.”
Pai, R., Barua, S., Kim, B. S., McDonald, M., Wierzchowska-McNew, R. A., Pai, A., Deutz, N. E. P., Kerr, D. E., & Sabharwal, A. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241274800 · Cited by 12
“34 In T1D and insulin-treated T2D, there is a solid evidence base for the use of CGM. 35,36 Recently, there has been growing interest in the use of CGM among adults with T2D including those not using insulin.”
Sinclair, M. R., Ardehali, M. M., Diamantidis, C. J., & Corsino, L. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1412874 · Cited by 10
Lee, C., Lui, D. T. W., Mak, L., Fong, C. H.-Y., Chan, K. S., Mak, J. H., Cheung, C. Y. Y., Chow, W., Woo, Y. C., Yuen, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16049 · Cited by 12
“24 27 Given the complex pathophysiology of steatohepatitis and the relatively small treat-ment effect with each individual agent, combination therapy for treating MASH has also been proposed.”
Osumili, B., Sapin, H., Yang, Z., Ranta, K., Paik, J. S., & Blüher, M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01728-5 · Cited by 16
“…acknowledge the importance of obesity management and recommend diet and lifestyle interventions for patients with T2DM who are overweight or have obesity; if needed, diet and lifestyle interventions should be supplemented with an antihyperglycaemic agent with proven weight loss benefits [5, 6].”
Maida, E., Caruso, P., Bonavita, S., Abbadessa, G., Miele, G., Longo, M., Scappaticcio, L., Ruocco, E., Trojsi, F., Esposito, K., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124240 · Cited by 15
“Additionally, the management of DM has to address not only glucose-lowering therapy but also the control of the other cardiovascular risk factors and related comorbidities [3].”
Pantalone, K. M., Xiao, H., Bena, J., Morrison, S. M., Downie, S., Boyd, A., Shah, L., Willis, B., Beharry-Diaz, J., Milinovich, A., et al. (2025) · NEJM Catalyst · doi:10.1056/cat.25.0016 · Cited by 17
Management of Diabetic Wounds: Expert Panel Consensus Statement
Hsia, H. C., Eriksson, E. K., Gurtner, G. C., Veves, A., Hamdy, O., Margolis, D. J., Armstrong, D. G., Lavery, L. A., Grice, E., Schultz, G., et al. (2025) · Advances in Wound Care · doi:10.1177/21621918251366586 · Cited by 18
“At present, greater emphasis is directed toward mitigating cardiovascular disease (CVD) 19 and chronic kidney disease 18 through pharmacological interventions in the management of T2DM.”
Short-Chain Fatty Acids as Bacterial Enterocytes and Therapeutic Target in Diabetes Mellitus Type 2
Neag, M. A., Craciun, A. E., Inceu, A.-I., Burlacu, D.-E., Crăciun, C.-I., & Buzoianu, A. D. (2022) · Biomedicines · doi:10.3390/biomedicines11010072 · Cited by 12
Ghalichi, F., Saghafi‐Asl, M., Kafil, B., Faghfouri, A. H., Rajabi-Jourshari, M., Naserkiadeh, A. A., & Ostadrahimi, A. (2023) · Biological Trace Element Research · doi:10.1007/s12011-023-03604-4 · Cited by 11
“In 2022, the Centers for Disease Control and Prevention (CDC) claimed that approximately 133 million Americans were living with diabetes or prediabetes [3].”
BackgroundTherapy of Type 2 diabetes: more gliflozines and less metformin?
Verdecchia, P., Murdolo, G., Coiro, S., Santucci, A., Notaristefano, F., Angeli, F., & Cavallini, C. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad098 · Cited by 10
“In summary, as indicated in Table 1, the ADA/EASD guidelines continue to recommend metformin as first-choice drug in patients with T2DM, either newly diagnosed or long-lasting, at high or low risk, with or without previous major CV events.(10,14) If heart failure or chronic kidney disease prevail in the individual pat…”
Grbić, E., Petrovič, M. G., Cilenšek, I., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11082303 · Cited by 10
“The current American Diabetes Association criteria were used to identify patients with T2DM [34].”
MethodInfluentialBrīvība, M., Silamiķele, L., Kalniņa, I., Silamiķelis, I., Birzniece, L., Ansone, L., Jagare, L., Elbere, I., & Kloviņš, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1232143 · Cited by 13
“In the management of diabetes mellitus, metformin (dimethylbiguanide) is still considered the first-choice pharmacological treatment for most patients because of its relatively high efficacy, affordable price, and safety (1).”
BackgroundIncretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease
Alicic, R. Z., & Neumiller, J. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010201 · Cited by 16
Wang, P., Zhang, Y., Xu, W., He, J., Peng, L., Feng, Y., Xu, P., Chong, W., Hai, Y., Jia, L., et al. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01240-5 · Cited by 10
“The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [24] have not yet included recommendations specific to this insulin formulation in their guidelines.”
BackgroundYuan, K., Wang, H., Chen, Y., Li, S., Wang, Q., Cao, Y.-M., Gao, S., Xu, X., & Xie, Q. (2020) · Annals of Palliative Medicine · doi:10.21037/apm.2020.03.16 · Cited by 11
Chan, V. W., Chan, P., Woo, Y., Fu, H., Cheung, A., Cheung, M., Yan, C., & Chiu, P. (2020) · Hong Kong Medical Journal · doi:10.12809/hkmj208459 · Cited by 14
Profiling of patients with type 2 diabetes based on medication adherence data
Markovič, R., Grubelnik, V., Završnik, T., Vošner, H. B., Kokol, P., Perc, M., Marhl, M., Završnik, M., & Završnik, J. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1209809 · Cited by 13
“This finding is in line with existing literature, which reports that metformin (a biguanide) is often the first-line treatment for T2DM, followed by sulfonylureas as an additional therapy when needed (51).”
ResultDiabetocardiology: a new subspecialty?
Braunwald, E. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad541 · Cited by 11
Optimizing GLP-1 therapies for obesity and diabetes management
Noronha, J. C., Gaal, L. F. V., Neeland, I. J., Fitch, A., Pfeiffer, A. F. H., Chiavaroli, L., Kendall, C. W. C., & Sievenpiper, J. L. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100222 · Cited by 21
“Glucagon-like peptide-1 (GLP-1) therapies, including liraglutide and semaglutide, have emerged as key treatments for obesity and type 2 diabetes management [1,2].”
Shariat‐Madar, Z., & Mahdi, F. (2025) · Molecules · doi:10.3390/molecules30224448 · Cited by 18
“However, clinical end-points meaningful to both clinicians and patients—such as health and well-being—remain essential [23].”
Hespanhol, L. C., Agarwal, S., Carvalhal, G., Bisneto, O. I. D. M., Chagas, G. C. L., Galindo, R. J., & Abreu, M. (2026) · Diabetes Care · doi:10.2337/dc25-2435 · Cited by 11
Sodium-glucose co-transporter-2 inhibitors: know the patient and the drugs
Lim, L., & Chan, J. C. N. (2019) · Hong Kong Medical Journal · doi:10.12809/hkmj195089 · Cited by 9
Emerging Preventive Strategies in Chronic Kidney Disease: Recent Evidence and Gaps in Knowledge
Pradhan, N., & Dobre, M. A. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01172-5 · Cited by 16
Lannoo, M., Simoens, C., Vangoitsenhoven, R., Gillard, P., D’Hoore, A. J. L., Vadder, M. D., Mertens, A. C., Deleus, E., Steenackers, N., Mathieu, C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-59048-w · Cited by 13
Self-citationNewson, R. S., Divino, V. M., Boye, K. S., Chen, J., DeKoven, M., Vallarino, C. R., Ranta, K., & Mount, J. E. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01583-w · Cited by 14
“Recent guidelines from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) have recognized the importance of weight management in T2D [22].”
BackgroundHaluzík, M., Taybani, Z. J., Araszkiewicz, A., Cerghizan, A., Mankovsky, B., Zuhdi, A., & Malecki, M. T. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01610-w · Cited by 12
“Poor glycaemic control is likely to be multifactorial and often arises from the delay in advancing therapy, often referred to as therapeutic inertia, affecting about 50% of the people with T2D [9, 10].”
BackgroundBeyond Glucose Monitoring: Multianalyte Sensor Use in Diabetes
Zhou, K., James, S., Gaca, M., Lecamwasam, A., Dervisevic, M., O'Neal, D. N., Voelcker, N. H., & Ekinci, E. I. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2024.0250 · Cited by 11
“6,28,29 However, current ketone monitoring methods only provide periodic information and measurements need to be initiated by the patient, often after DKA has occurred.”
Kakoschke, N., Henry, B. A., Cowley, M. A., & Lee, K. (2024) · Nutrients · doi:10.3390/nu16193238 · Cited by 12
“An example of a holistic person-centred approach for diabetes management was recently published in a consensus statement by the American Diabetes Association and the European Association for the Study of Diabetes in 2022 [108].”
BackgroundLi, J., Yoshimura, K., Sasaki, M., & Maruyama, K. (2024) · Nutrients · doi:10.3390/nu16234013 · Cited by 22
Characteristics and Dosing Patterns of Tirzepatide Users with Type 2 Diabetes in the United States
Mody, R., Desai, K. R., Teng, C., Reznor, G., Stockbower, G. E., Grabner, M., & Benneyworth, B. D. (2025) · Diabetes Therapy · doi:10.1007/s13300-024-01684-6 · Cited by 15
Xu, L., Wu, Y., Li, J., Ding, Y., Chow, J., Li, L., Liu, H., Wang, Z., Gong, T., Li, Y., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-088687 · Cited by 12
Liu, X., Xie, J., Hou, J., Xu, X., & Guo, Y. (2025) · Journal of Medical Systems · doi:10.1007/s10916-025-02165-4 · Cited by 12
Cost-of-illness analysis of chronic kidney disease (CKD) management in the Philippines
Villanueva, A. R., Leon, D. F. D., Encarnacion, P. J., Cunanan, E., Estabillo, A. P., Gonzales, C. J., Kimwell, M. J., Mallari-Catungal, M., Taneo, M. J., Tan-Lim, D. D., et al. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2481766 · Cited by 13
Type 2 Diabetes Mellitus and bladder cancer: A narrative review on associated signaling pathways
Agostini, L. D. C., & da Silva, G. N. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101381 · Cited by 11
Horváth, L., Novodvorský, P., & Haluzík, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16645 · Cited by 10
“16,17 Fixed-ratio combinations of basal insulin analogues and GLP-1 RA (FRC) benefit from complementary mechanisms of action of their two components that cumulatively influence most of the aforementioned processes in the pathogenesis of T2DM.”
Xu, C., Meng, Z., Lin, W., Li, H., Xu, Q., Zhao, K., Chen, Y., Wang, Y., Zou, W., Kuang, B., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118409 · Cited by 12
From Current Therapeutics to Multitarget Ligands: A Review of Diabetes Pharmacological Treatments
Cabré, F., Centelles, J. J., & Cascante, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091125 · Cited by 16
Koufakis, T., Liberopoulos, E. N., Kokkinos, A. D., Zebekakis, P. E., & Kotsa, K. (2023) · Drugs · doi:10.1007/s40265-023-01852-1 · Cited by 9
“For these reasons, in the recent American Diabetes Association/ European Association for the Study of Diabetes consensus, metformin has lost its place as the first-line treatment for all patients with T2D, and a more individualized approach based on weight and CV risk assessment is proposed [36].”
BackgroundCorbacho-Alonso, N., Rodríguez‐Sánchez, E., Sastre-Oliva, T., Mercado‐García, E., Perales-Sánchez, I., Juárez-Alia, C., Lopez-Almodovar, L. F., Padial, L. R., Tejerina, T., Mouriño-Álvarez, L., et al. (2023) · Antioxidants · doi:10.3390/antiox12051024 · Cited by 9
Martínez, J. J. G., Ferreira-Ocampo, P. J., Sanz-Pastor, A. G., Cárdenas‐Salas, J., Antón-Bravo, T., Brito-Sanfiel, M. Á., & Ruiz, F. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134248 · Cited by 11
“This strategy, not included in recent guidelines [16], would avoid the need for prescribing new GLDs on top of the current treatment, thereby reducing the treatment burden and complexity.”
BackgroundKokkinos, P. F., Nylén, E., Faselis, C. J., Pittaras, A. E., Samuel, I. B. H., Lavie, C. J., Doumas, M. N., Heimall, M. S., Murphy, R., & MYERS, J. N. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.05.005 · Cited by 9
Sugawara, M., Fukuda, M., Sakuma, I., Wakasa, Y., Funayama, H., Kondo, A., Itabashi, N., Maruyama, Y., Kamiyama, T., Utsunomiya, Y., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01438-w · Cited by 10
“Following the approval and launch of dipeptidylpeptidase 4 inhibitors (DPP-4is) and sodiumglucose cotransporter 2 inhibitors (SGLT2is), the current consensus statements of ADA and EASD were modified to recommend the use of SGLT2is and glucagon-like peptide 1 receptor (GLP1R) agonists owing to the associated beneficial…”
BackgroundInfluentialPérez-Gómez, N., Fernández-Ortega, M. D., Elizari-Roncal, M., Mazo, E. S., Pereg, L. D. L. M., Calvo, S., Alcaraz, R., Sanz-Solas, A., Campo, R. V., & Saiz‐Rodríguez, M. (2023) · Pharmacogenomics · doi:10.2217/pgs-2023-0109 · Cited by 11
An Update on Semaglutide Research: A Bibliometric Analysis and a Literature Review
Dagli, N., Kumar, S., Ahmad, R., Narwaria, M., & Haque, M. (2023) · Cureus · doi:10.7759/cureus.46510 · Cited by 17
“A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) on managing T2DM mentioned that semaglutide is highly effective for weight management in people with type 2 diabetes [25].”
BackgroundDiabetes care in older people: a call for action
Muskiet, M. H. A., Elders, P. J. M., & van Raalte, D. H. (2023) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(23)00234-9 · Cited by 9
The European List of Key Medicines for Medical Education: A Modified Delphi Study
Donker, E. M., Timpone, P. S., Brinkman, D. J., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3132 · Cited by 9
“42 In some European countries, SU derivates have been removed from prescribing guidelines, 43 whereas in others these medicines are still the second choice for patients without prior cardiovascular or renal disease.”
BackgroundKe, C., Shah, B. R., Thiruchelvam, D., & Echouffo-Tcheugui, J. B. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.030683 · Cited by 11
Loreto, C. D., Celleno, R., Pezzuto, D., Ambrosi, F., Bellavita, S., Biagini, M., Passeri, M., & Sindaco, P. D. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01564-z · Cited by 12
“Both glucagon-like peptide 1 receptor agonists (GLP-1RA) and basal insulin are now recommended treatment options for intensification at many stages of T2D, with the potential of overcoming clinical inertia [3].”
BackgroundInfluentialLyngbæk, M. P. P., Legaard, G. E., Nielsen, N. S., Durrer, C. G., Almdal, T., Lund, M. A. V., Liebetrau, B., Ewertsen, C., Lauridsen, C. A., Solomon, T. P. J., et al. (2024) · Journal of sport and health science/Journal of Sport and Health Science · doi:10.1016/j.jshs.2024.100999 · Cited by 11
“4,12 Consequently, interventions for people with type 2 diabetes that facilitate a reduction in excessive FM while preserving FFM are warranted.”
Amelia, R., Harahap, J., Lelo, A., et al. (2020) · Family Medicine & Primary Care Review · doi:10.5114/fmpcr.2020.98242 · Cited by 9
He, L., Zheng, W., Li, Z., Kong, W., & Zeng, T. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01790-7 · Cited by 11
Zhang, Y., Jiang, L., Xue, J., Lv, M., & Zhang, W. (2023) · Medicine · doi:10.1097/md.0000000000033481 · Cited by 10
“[22,23] According to the guidelines, the use of renin-angiotensin-aldosterone system inhibitors (angiotensin converting enzyme inhibitors [ACEI] or angiotensin receptor blockers [ARB]) and sodium-glucose cotransporter 2 (SGLT2) inhibitors to control hypertension and hyperglycemia has been shown to have a positive effe…”
MethodInfluentialCazac, G.-D., Lăcătușu, C.-M., Ștefănescu, G., Mihai, C., Grigorescu, E.-D., Onofriescu, A., & Mihai, B. M. (2023) · Metabolites · doi:10.3390/metabo13050581 · Cited by 10
“Along with sodium-glucose cotransporter 2 (SGLT2) inhibitors, GLP-1RAs have become the first-line therapy for T2DM due to their potent glucose-lowering effects and their ability to reduce the cardiovascular risk irrespective of the glycemic improvement or the weight loss [23].”
BackgroundGovardhane, S., & Shende, P. K. (2023) · Journal of Liposome Research · doi:10.1080/08982104.2023.2209642 · Cited by 10
“…insulin, drugs like metformin, sulfonylureas, a -Glucosidase inhibitors, etc. are susceptible to gastrointestinal side effects (diarrhea, abdominal pain, flatulence), weight gain, pancreatitis, and cardiovascular safety issues like atherosclerosis, high blood pressure, etc. (Davies et al. 2022).”
BackgroundGe, Z., Li, C., Li, Y., Wang, N., & Hong, Z. (2024) · INQUIRY The Journal of Health Care Organization Provision and Financing · doi:10.1177/00469580241235755 · Cited by 13
“…the importance of single or combined lifestyle interventions, such as a balanced diet, smoking cessation and alcohol restriction, and regular exercise, for managing body weight, 29 regulating metabolic markers, 4,30 improving prognosis, 31 and decreasing the risk of death 5,28,32 in older adults.”
BackgroundDiabetes: Recent Advances and Future Perspectives
Janić, M., Janež, A., El‐Tanani, M., Maggio, V., & Rizzo, M. (2024) · Biomedicines · doi:10.3390/biomedicines12122875 · Cited by 14
Khemtong, A., Shantavasinkul, P. C., Boonchaya‐anant, P., Rattanasiri, S., Treeprasertsuk, S., & Udomsawaengsup, S. (2024) · Journal of Laparoendoscopic & Advanced Surgical Techniques · doi:10.1089/lap.2023.0391 · Cited by 9
“8 The most obvious effect of VLCD is the significant and rapid weight loss, which leads to liver shrinkage 23,24 and improves the technical aspect of surgery.”
Chan, Y., Chao, T., Chen, S., Lee, H., Li, P., Yeh, Y., Kuo, C.-T., See, L., & Lip, G. Y. H. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae157 · Cited by 8
Metadata
- Authors
- Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B.
- Affiliations
- University of Leicester (GB)
- Brigham and Women's Hospital (US)
- National Heart, Lung, and Blood Institute (US)
- American Diabetes Association (US)
- Duke University (US)
- Johns Hopkins University (US)
- Joslin Diabetes Center (US)
- 9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- KU Leuven (BE)
- Università Cattolica del Sacro Cuore (IT)
- University of Copenhagen (DK)
- Medical University of Sofia (BG)
- 17Diabetes Centre, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-28
- Volume
- 45
- Issue
- 11
- Pages
- 2753-2786
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC10008140
- OpenAlex
- W4296802076
- Cited by
- 2,104
- References
- 348
- Citations by year
- 2026: 500 · 2025: 567 · 2024: 509 · 2023: 396 · 2022: 50
- FWCI
- 282.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- European Association for the Study of Diabetes
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, glycemic targets, social determinants of health, physical activity, sleep, weight management, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, renal outcomes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.